Ferreira Meghaan M, Ramani Vishnu C, Jeffrey Stefanie S
Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
Mol Oncol. 2016 Mar;10(3):374-94. doi: 10.1016/j.molonc.2016.01.007. Epub 2016 Jan 28.
Circulating tumor cells, a component of the "liquid biopsy", hold great potential to transform the current landscape of cancer therapy. A key challenge to unlocking the clinical utility of CTCs lies in the ability to detect and isolate these rare cells using methods amenable to downstream characterization and other applications. In this review, we will provide an overview of current technologies used to detect and capture CTCs with brief insights into the workings of individual technologies. We focus on the strategies employed by different platforms and discuss the advantages of each. As our understanding of CTC biology matures, CTC technologies will need to evolve, and we discuss some of the present challenges facing the field in light of recent data encompassing epithelial-to-mesenchymal transition, tumor-initiating cells, and CTC clusters.
循环肿瘤细胞作为“液体活检”的一个组成部分,在改变当前癌症治疗格局方面具有巨大潜力。要发挥循环肿瘤细胞的临床应用价值,一个关键挑战在于能否使用适合下游特征分析及其他应用的方法来检测和分离这些稀有细胞。在本综述中,我们将概述目前用于检测和捕获循环肿瘤细胞的技术,并简要介绍各项技术的工作原理。我们重点关注不同平台所采用的策略,并讨论每种策略的优势。随着我们对循环肿瘤细胞生物学的理解不断成熟,循环肿瘤细胞技术也需要不断发展,我们将根据最近有关上皮-间质转化、肿瘤起始细胞和循环肿瘤细胞簇的数据,讨论该领域目前面临的一些挑战。